Morphine and methadobe diiference

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Here is a detailed comparison of Morphine vs. Methadone:

Morphine vs. Methadone - Key Differences

1. Chemical Class & Structure

Feature	Morphine	Methadone
Origin	Natural alkaloid (opium poppy)	Synthetic opioid (phenylethylamine class)
Structure	Benzylisoquinoline	Structurally unrelated to morphine

Methadone is a synthetic opioid of the phenylethylamine class, structurally unrelated to morphine. - Kaplan & Sadock's Comprehensive Textbook of Psychiatry

2. Mechanism of Action

Feature	Morphine	Methadone
Primary receptor	mu (μ) opioid agonist	mu (μ) opioid agonist
Additional mechanisms	None	Also: NMDA receptor antagonist + norepinephrine & serotonin reuptake inhibitor

Methadone is a μ agonist, an antagonist of the NMDA receptor, and a norepinephrine and serotonin reuptake inhibitor. Therefore, it is useful in the treatment of both nociceptive and neuropathic pain - while morphine is primarily useful for nociceptive pain. - Lippincott Pharmacology

3. Pharmacokinetics

Feature	Morphine	Methadone
Oral bioavailability	20-40%	36-100% (much higher, but variable)
Half-life	2-4 hours	12-40 hours (can extend up to 150 hours)
Duration of analgesia	4-6 hours	4-8 hours (shorter than its half-life suggests)
Steady state	Rapid	35 hours to 2 weeks
Metabolism	Glucuronidation (NOT CYP450)	CYP2B6 and CYP3A4 (many drug interactions)
Active metabolites	Yes (morphine-6-glucuronide - active; morphine-3-glucuronide - neuroexcitatory)	No active metabolites

The key danger with methadone: its analgesic duration is only 4-8 hours, but its half-life is 12-150 hours. This mismatch means repeat dosing for pain can lead to dangerous accumulation and respiratory depression. - Lippincott Pharmacology

4. Equianalgesic Dosing

The morphine:methadone ratio is not linear - it is curvilinear and depends on the prior morphine dose:

Daily Oral Morphine Dose	Morphine:Methadone Ratio
< 100 mg/day	~4:1
100-300 mg/day	~8:1
300-1000 mg/day	~12:1
> 1000 mg/day	~20:1 (e.g. 1200 mg morphine = 60 mg methadone)

Because cross-tolerance is incomplete, the calculated equianalgesic dose of any new opioid is always lower than expected. One must be particularly cautious when converting from morphine to methadone, as the morphine:methadone equianalgesic ratio appears to be curvilinear. - Barash Clinical Anesthesia

5. Adverse Effects Comparison

Side Effect	Morphine	Methadone
Constipation	Yes	Yes (but less than morphine)
Neurotoxicity / active metabolites	Yes (M3G can cause seizures/myoclonus)	Less - no active metabolites
QTc prolongation / Torsades de Pointes	No significant risk	Yes - baseline and routine ECG monitoring required
Respiratory depression risk	Yes	Higher risk due to long/unpredictable half-life
Sedation/euphoria	Yes	Less euphoria than morphine

6. Clinical Uses

Use	Morphine	Methadone
Acute/post-op pain	First-line	Not preferred (unpredictable PK)
Chronic cancer pain	Yes	Yes - especially when morphine tolerance has developed
Neuropathic pain	Limited	Yes (via NMDA antagonism)
Opioid use disorder (OUD) treatment	No	Yes - gold standard for maintenance therapy (50-100 mg/day)
Opioid detox	No	Yes - low doses (5-10 mg BID/TID) for 2-3 days

When analgesic tolerance or intolerable side effects develop with morphine or hydromorphone in cancer pain, "opioid rotation" to methadone has provided superior analgesia at 10-20% of the morphine-equivalent daily dose. - Katzung's Basic and Clinical Pharmacology

7. Tolerance & Dependence

Tolerance and physical dependence develop more slowly with methadone than with morphine
Withdrawal with methadone is milder but more prolonged (days to weeks) compared to morphine
Methadone induces less euphoria, reducing abuse potential compared to morphine

Summary Table

Property	Morphine	Methadone
Class	Natural opioid	Synthetic opioid
Receptor	μ agonist only	μ agonist + NMDA antagonist + NE/5HT reuptake inhibitor
Half-life	~2-4 hours	12-150 hours (highly variable)
Oral bioavailability	20-40%	36-100%
Active metabolites	Yes (M6G, M3G)	No
QTc prolongation	No	Yes
Neuropathic pain	Poor	Good
OUD treatment	No	Yes
Drug interactions	Low (no CYP450)	High (CYP2B6, CYP3A4)
Constipation	++++	+++

Sources: Lippincott Illustrated Reviews Pharmacology, Katzung's Basic and Clinical Pharmacology 16e, Barash Clinical Anesthesia 9e, Kaplan & Sadock's Comprehensive Textbook of Psychiatry

Give me 15 case based mcqs about pharmacology on the topic Opiod drugs classification and mechanism like that change the order without answers from and katzung and lippincott as well

Finding Sources

Reading File

Finding Sources

Here are 15 case-based MCQs on Opioid Drugs - Classification & Mechanism of Action, sourced from Katzung's Basic and Clinical Pharmacology (16e), Lippincott Illustrated Reviews: Pharmacology, and Goodman & Gilman's.

Opioid Pharmacology - Case-Based MCQs

Q1. A 55-year-old man with stage IV lung cancer is admitted with severe chronic pain unresponsive to NSAIDs. His physician starts him on a drug that acts as a 7-transmembrane G protein-coupled receptor (GPCR) agonist and is described as the "mainstay of pain treatment." The primary receptor responsible for its analgesic effect also mediates its major adverse effects. Which receptor type is primarily responsible for both the analgesic and unwanted effects of this class of drugs?

a) Delta (δ) opioid receptor b) Kappa (κ) opioid receptor c) Mu (μ) opioid receptor d) Nociceptin/ORL-1 (NOPr) receptor

Q2. A pharmacology student is reviewing opioid classification. She learns that opium contains several alkaloids. One compound in opium has no opioid activity itself but is used as a starting material for synthesizing multiple opioid drugs in the laboratory. Which compound is she reading about?

a) Codeine b) Papaverine c) Noscapine d) Thebaine

Q3. A 32-year-old woman with heroin use disorder is enrolled in a maintenance program. She is started on an oral agent that is a full μ-receptor agonist with a half-life of 15-40 hours. Her clinician is concerned about a specific cardiac adverse effect not typically seen with other opioids. A baseline ECG is ordered. What is the primary cardiac risk with this drug?

a) Atrial fibrillation b) Atrioventricular block c) QTc prolongation and torsades de pointes d) Ventricular hypertrophy

Q4. A 68-year-old man with cancer pain is switched from oral morphine to a new agent because of intolerable nausea and itching with morphine. The new drug not only activates μ-opioid receptors but also blocks NMDA receptors and inhibits norepinephrine and serotonin reuptake. Which property explains why this drug is particularly effective for neuropathic pain, unlike morphine alone?

a) Higher oral bioavailability than morphine b) Lack of active metabolites causing less neurotoxicity c) NMDA receptor antagonism and monoamine reuptake inhibition d) Longer duration of analgesia due to extended half-life

Q5. A 28-year-old man is found unconscious with pinpoint pupils, bradycardia, and a respiratory rate of 4/min. Empty pill packets nearby suggest opioid ingestion. He is given an IV drug that rapidly reverses all his symptoms within 2 minutes. However, 90 minutes later, he becomes obtunded again. Which characteristic of the reversal agent best explains this recurrence?

a) The reversal agent is a partial agonist with a ceiling effect b) The reversal agent has a shorter duration of action (~1 hour) than most opioids c) The reversal agent undergoes first-pass metabolism when given intravenously d) The reversal agent only blocks kappa receptors, not mu receptors

Q6. A 7-year-old child is prescribed a common antitussive opioid after tonsillectomy. The drug is classified as a prodrug with minimal intrinsic analgesic activity. Two days later, the child is found unresponsive with severe respiratory depression. Genetic testing reveals the child is an ultra-rapid metabolizer of a specific enzyme. Which enzyme's polymorphism explains this life-threatening toxicity?

a) CYP3A4 b) CYP2C9 c) CYP1A2 d) CYP2D6

Q7. A 45-year-old patient with chronic low back pain is started on a weak opioid analgesic that also inhibits serotonin and norepinephrine reuptake. His psychiatrist is concerned because the patient is already on a selective serotonin reuptake inhibitor (SSRI). What is the major drug interaction risk in this patient?

a) Opioid withdrawal syndrome b) Serotonin syndrome c) Neuroleptic malignant syndrome d) QTc prolongation

Q8. A researcher is studying the classification of opioid ligands. She reads that a naturally derived compound is considered an "opiate," while a fully synthetic compound with the same receptor target is termed an "opioid." Which of the following pairs correctly distinguishes an opiate from an opioid?

a) Codeine (opiate) vs. Fentanyl (opioid) b) Fentanyl (opiate) vs. Morphine (opioid) c) Methadone (opiate) vs. Heroin (opioid) d) Naloxone (opiate) vs. Buprenorphine (opioid)

Q9. A patient with opioid use disorder is started on sublingual buprenorphine. The clinician explains that unlike methadone or heroin, this drug has a defined safety advantage related to its receptor pharmacology. Even at very high doses, the drug does not produce proportionally increasing respiratory depression. What property of buprenorphine accounts for this safety advantage?

a) It is a full agonist at kappa receptors, offsetting mu effects b) It is a pure antagonist at all opioid receptors c) It is a partial agonist at the mu receptor with a ceiling effect on respiratory depression d) It is rapidly inactivated by CYP3A4 before reaching the brain

Q10. A 60-year-old woman on long-term morphine for cancer pain develops tolerance and progressive loss of pain control. Her oncologist considers switching to methadone, noting that "opioid rotation" to methadone can provide superior analgesia at a fraction of the morphine-equivalent dose. During the rotation, the clinician reduces the calculated equianalgesic dose significantly. Why is a dose reduction mandatory when converting from high-dose morphine to methadone?

a) Methadone has lower oral bioavailability than morphine b) The morphine:methadone equianalgesic ratio is linear at high doses, overestimating the required methadone dose c) The morphine:methadone equianalgesic ratio is curvilinear - methadone becomes progressively more potent as prior morphine doses increase d) Methadone undergoes complete first-pass metabolism that reduces its effective concentration

Q11. A 50-year-old male cancer patient requires around-the-clock moderate-to-severe pain management with opioids. He also has a history of renal failure. His physician avoids morphine due to accumulation of a neuroexcitatory active metabolite and instead chooses methadone. Which metabolite of morphine is most responsible for this concern?

a) Morphine-6-glucuronide (M6G) b) Morphine-3-glucuronide (M3G) c) Normorphine d) Hydromorphone

Q12. A 38-year-old woman is prescribed a fentanyl transdermal patch for chronic severe pain. She is warned about the delayed onset and prolonged effect of this formulation. The patch creates a drug reservoir in the skin, resulting in an onset of at least 12 hours. What is the primary pharmacokinetic property of fentanyl that makes the transdermal route feasible?

a) Low molecular weight and high water solubility b) High lipophilicity enabling absorption through the skin c) Extensive plasma protein binding preventing renal clearance d) Metabolism by glucuronidation allowing slow release

Q13. A 25-year-old man with heroin use disorder undergoes detoxification. He is given low doses of an oral full μ-agonist opioid (5-10 mg, two to three times daily for 2-3 days) to suppress the acute withdrawal syndrome. The drug chosen has a long half-life, making abrupt discontinuation produce a withdrawal syndrome that is milder than heroin's but significantly more prolonged. Which drug is being described?

a) Buprenorphine b) Naltrexone c) Methadone d) Codeine

Q14. A group of opioid compounds is described in a pharmacology lecture as exhibiting "clinically useful analgesia but with less respiratory depression and addictive potential compared to full mu-agonists." These drugs are not selective for the mu receptor over the delta or kappa receptors as compared to high-efficacy mu agonists. Which class of opioids is being described?

a) Full mu-opioid receptor agonists (e.g., morphine) b) Opioid antagonists (e.g., naloxone) c) Partial opioid agonists (e.g., buprenorphine, pentazocine) d) Mixed agonist-antagonists acting only on kappa receptors

Q15. A 40-year-old patient on chronic high-dose morphine for cancer develops intolerable myoclonus and seizures. His palliative care physician attributes this to accumulation of a neuroexcitatory morphine metabolite, which is more prominent in renal failure. The physician also notes that morphine has a lower drug-interaction risk compared to methadone because it avoids a specific metabolic pathway. Which metabolic pathway does morphine NOT rely on, giving it fewer drug interactions?

a) Glucuronidation (UGT enzymes) b) CYP2D6 oxidation c) CYP3A4 / CYP2B6 hepatic oxidation d) Renal excretion of unchanged drug

Sources: Katzung's Basic and Clinical Pharmacology 16e | Lippincott Illustrated Reviews: Pharmacology | Goodman & Gilman's Pharmacological Basis of Therapeutics

C B C C B D B B C C A B C C C

Here is your answer key with explanations:

Answer Key & Explanations

Q1. Answer: C - Mu (μ) opioid receptor The mu-opioid receptor is mainly responsible for the pain-relieving actions and, importantly, also the unwanted effects (respiratory depression, constipation, dependence) of all clinically useful opioid analgesics. (Goodman & Gilman's)

Q2. Answer: B - Thebaine ✅ Thebaine has no opioid activity itself but serves as a precursor for synthesis of additional opioid drugs (e.g., oxycodone, buprenorphine). Papaverine is a smooth muscle relaxant; noscapine is an antitussive. (Goodman & Gilman's)

Q3. Answer: C - QTc prolongation and torsades de pointes ✅ Methadone is uniquely associated with QTc prolongation and torsades de pointes, possibly by interacting with cardiac potassium channels - unlike other opioids. Baseline and routine ECG monitoring is recommended. (Lippincott)

Q4. Answer: C - NMDA receptor antagonism and monoamine reuptake inhibition ✅ Methadone is a μ agonist + NMDA receptor antagonist + norepinephrine and serotonin reuptake inhibitor. This dual mechanism makes it effective for both nociceptive AND neuropathic pain, where morphine (pure mu agonist) often fails. (Lippincott)

Q5. Answer: B - The reversal agent has a shorter duration of action (~1 hour) than most opioids ✅ Naloxone has a relatively short duration of action (~1 hour). Many opioids, especially after overdose, last significantly longer. Patients who respond to naloxone must be observed for recurrence of respiratory depression and may require repeat doses. (Lippincott / Rosen's)

Q6. Answer: D - CYP2D6 ✅ Codeine is a prodrug that is converted to morphine (its active metabolite) by CYP2D6. Ultra-rapid metabolizers convert codeine to morphine much faster and in greater amounts, causing morphine toxicity and respiratory depression - a well-documented fatal risk especially in children post-tonsillectomy. (Katzung / Morgan & Mikhail)

Q7. Answer: B - Serotonin syndrome ✅ Tramadol inhibits both serotonin and norepinephrine reuptake. When combined with an SSRI, the additive serotonergic effect can precipitate serotonin syndrome (agitation, hyperthermia, clonus, autonomic instability). (Goodman & Gilman's / Rheumatology textbook)

Q8. Answer: B - Codeine (opiate) vs. Fentanyl (opioid) Your answer was B. The correct answer is A - Codeine (opiate) vs. Fentanyl (opioid).

Opiates = naturally derived compounds from opium (morphine, codeine)
Opioids = broader term covering opiates + fully synthetic drugs (fentanyl, methadone) + endogenous peptides
Fentanyl is fully synthetic, making it an opioid but NOT an opiate
Codeine is derived from opium, making it an opiate (Goodman & Gilman's)

Q9. Answer: C - Partial agonist at the mu receptor with a ceiling effect on respiratory depression ✅ Buprenorphine is a partial high-affinity μ-agonist. Its partial agonist nature means it has a ceiling effect - beyond a certain dose, respiratory depression does not continue to increase proportionally, giving it a wider safety margin than full agonists. (Goodman & Gilman's / Barash)

Q10. Answer: C - Curvilinear ratio - methadone becomes progressively more potent as prior morphine doses increase ✅ The morphine:methadone equianalgesic ratio is curvilinear. At low morphine doses the ratio is ~4:1, but at very high doses (>1000 mg/day morphine) it becomes ~20:1. This means methadone is far more potent than expected at high morphine-equivalent doses - requiring a significant dose reduction to avoid toxicity. (Barash Clinical Anesthesia)

Q11. Answer: A - Morphine-6-glucuronide (M6G) Your answer was A. The correct answer is B - Morphine-3-glucuronide (M3G).

M3G is the neuroexcitatory metabolite responsible for myoclonus, seizures, and hyperalgesia - it accumulates in renal failure
M6G is actually the active analgesic metabolite (more potent than morphine itself) - its accumulation causes excess sedation and respiratory depression in renal failure
The myoclonus/seizures described in the question point specifically to M3G (Lippincott)

Q12. Answer: B - High lipophilicity enabling absorption through the skin ✅ Fentanyl is highly lipophilic, which allows it to penetrate the skin and form a drug reservoir in the subcutaneous tissue. This lipophilicity is the key pharmacokinetic property that makes transdermal delivery feasible. (Lippincott)

Q13. Answer: C - Methadone ✅ For detoxification, low doses of methadone (5-10 mg orally, 2-3 times daily for 2-3 days) are used to suppress acute withdrawal. Methadone's long half-life (15-40 hours) means withdrawal after it is stopped is milder but significantly more prolonged than morphine or heroin withdrawal. (Goodman & Gilman's / Katzung)

Q14. Answer: C - Partial opioid agonists ✅ Partial agonists (buprenorphine, pentazocine) exhibit clinically useful analgesia with less respiratory depression and addictive potential. They are not highly selective for mu over delta or kappa receptors compared to high-efficacy mu agonists like morphine. (Goodman & Gilman's)

Q15. Answer: C - CYP3A4 / CYP2B6 hepatic oxidation ✅ Morphine is metabolized primarily by glucuronidation (UGT enzymes), NOT by the CYP450 system. This means it has far fewer drug-drug interactions compared to methadone, which relies heavily on CYP2B6 and CYP3A4 - enzymes subject to inhibition and induction by many common drugs. (Lippincott)

Score Summary

Result	Count
✅ Correct	13/15
❌ Incorrect	2/15

Incorrect:

Q8 - You answered B; correct is A (Codeine = opiate, Fentanyl = opioid)
Q11 - You answered A; correct is B (M3G causes neuroexcitation/seizures; M6G causes sedation/respiratory depression)

Score: 13/15 (87%) - Excellent performance! The two missed questions both test fine distinctions in opioid metabolite and classification terminology - worth reviewing.

few more

Finding Sources

Here are 10 more case-based MCQs - covering deeper topics like endogenous opioids, tolerance mechanisms, receptor signalling, and antagonists:

Opioid Pharmacology - MCQs (Set 2)

Q16. A neuroscience lecturer explains that endogenous opioid peptides arise from three major precursor proteins. She states: "One precursor gives rise to the endogenous peptides that preferentially activate delta receptors, another produces the primary endogenous ligand for mu receptors, and a third produces the endogenous ligands for kappa receptors." Which set correctly matches precursor to active peptide and receptor?

a) POMC → Dynorphins → κ receptor; Proenkephalin → β-Endorphin → μ receptor; Prodynorphin → Enkephalins → δ receptor b) Proenkephalin → Met/Leu-enkephalin → δ receptor; POMC → β-Endorphin → μ receptor; Prodynorphin → Dynorphins → κ receptor c) POMC → Enkephalins → δ receptor; Proenkephalin → Dynorphins → κ receptor; Prodynorphin → β-Endorphin → μ receptor d) Proenkephalin → β-Endorphin → κ receptor; Prodynorphin → Enkephalins → δ receptor; POMC → Dynorphins → μ receptor

Q17. A patient on chronic morphine for back pain notices his pain relief has progressively decreased over 6 months, requiring higher doses to achieve the same effect. His physician explains the molecular basis: opioid receptors initially inhibit adenylyl cyclase, but after repeated exposure this inhibition weakens and the cAMP-CREB pathway becomes upregulated to restore normal activity. What phenomenon is being described?

a) Physical dependence b) Opioid rotation c) Pharmacokinetic tolerance d) Pharmacodynamic tolerance

Q18. A 55-year-old chronic pain patient on long-term morphine abruptly stops taking his medication. Within 8 hours he develops anxiety, yawning, lacrimation, rhinorrhea, sweating, and piloerection. His heart rate is 110 bpm. His physician notes these symptoms represent activation of an adrenergic nucleus that is normally suppressed by opioids. Which brain region, when disinhibited during opioid withdrawal, produces most of these autonomic symptoms?

a) Periaqueductal gray b) Nucleus accumbens c) Locus coeruleus d) Dorsal raphe nucleus

Q19. A 35-year-old male with opioid use disorder achieves sobriety and is started on a once-daily oral drug that competitively blocks mu, delta, and kappa receptors. He is warned that if he uses heroin while on this drug, he will feel no euphoria. Six months later, he is also found to have alcohol use disorder - and his physician notes this same drug is FDA-approved for that condition too. Which drug is this?

a) Methadone b) Buprenorphine c) Clonidine d) Naltrexone

Q20. A pharmacology exam question describes a patient who takes a kappa-opioid agonist for pain. Instead of euphoria, the patient experiences dysphoria, sedation, and disturbing hallucinations. A classmate asks why kappa agonism produces dysphoria rather than euphoria. Which receptor type, when predominantly activated, is responsible for euphoria in opioid use?

a) Delta (δ) receptor b) Kappa (κ) receptor c) Mu (μ) receptor d) Nociceptin (NOPr) receptor

Q21. A 72-year-old woman with cancer pain is on morphine. Her nurse asks why the attending physician ordered a laxative at the same time as the morphine, even though the patient is not yet constipated. The physician explains that unlike other side effects of opioids, tolerance to this particular effect does NOT develop with continued use. Which two opioid effects does tolerance NOT develop to?

a) Respiratory depression and euphoria b) Constipation and miosis (pupil constriction) c) Sedation and nausea d) Analgesia and urinary retention

Q22. A researcher studying opioid signal transduction explains that opioid receptors are Gi/Go protein-coupled receptors. Upon activation, three key cellular effects occur that collectively suppress neuronal excitability and neurotransmitter release. Which combination correctly describes the downstream effects of opioid receptor activation?

a) Increased cAMP, calcium channel opening, potassium channel closure b) Decreased cAMP, calcium channel inhibition, potassium channel opening (hyperpolarization) c) Increased cAMP, potassium channel opening, sodium channel closure d) Decreased cAMP, sodium channel opening, calcium channel activation

Q23. A patient on chronic methadone maintenance presents to the ER with a supratherapeutic methadone level after his physician added rifampin for tuberculosis treatment. The patient is showing signs of opioid withdrawal despite taking his usual methadone dose. What is the mechanism by which rifampin caused this interaction?

a) Rifampin blocks mu-opioid receptors, competing with methadone b) Rifampin is a potent CYP enzyme inducer that accelerates methadone metabolism, reducing its plasma levels c) Rifampin inhibits renal excretion of methadone, causing toxicity not withdrawal d) Rifampin displaces methadone from plasma protein binding sites

Q24. A 48-year-old woman with chronic pain is started on a drug described as a "dual-action opioid." It is a weak mu-opioid agonist but also inhibits norepinephrine reuptake more selectively than serotonin reuptake - making it less likely to cause serotonin syndrome compared to tramadol. This drug is structurally and mechanistically similar to tramadol but with more potent opioid activity. Which drug is being described?

a) Buprenorphine b) Tapentadol c) Oxycodone d) Methadone

Q25. A medical student reads that opioids produce analgesia via three anatomical levels. At the spinal cord level, mu-opioid receptors in the dorsal horn inhibit calcium influx and reduce substance P release. At the supraspinal level, a specific midbrain region activates descending inhibitory pathways to the dorsal horn. Opioids also act peripherally on sensory neurons at sites of inflammation. Which supraspinal region is the key site of opioid-mediated activation of descending pain inhibition?

a) Locus coeruleus b) Nucleus accumbens c) Periaqueductal gray (PAG) d) Substantia nigra

Sources: Katzung's Basic and Clinical Pharmacology 16e | Lippincott Illustrated Reviews: Pharmacology | Goodman & Gilman's | Barash Clinical Anesthesia 9e

This is a shared conversation. Sign in to Orris to start your own chat.